Sony and Astellas have recently announced a collaborative research agreement aimed at developing a new Antibody-Drug Conjugate (ADC) platform in oncology. The partnership will focus on Sony’s unique polymeric material, KIRAVIA™ Backbone, which can be used to create linkers that conjugate antibodies and drugs, a critical step in creating a better-performing ADC.
The ADC platform is expected to deliver anti-cancer drugs to targeted cells, thus improving the efficacy of treatment while reducing side effects caused by drugs attacking normal cells. The high capacity and solubility of the KIRAVIA Backbone as a linker of ADC are believed to increase therapeutic efficacy by achieving high Drug-to-Antibody Ratio (DAR). Sony and Astellas aim to create a new drug discovery platform for new value and combined technology, not limited to ADC.
The two companies are jointly developing and optimizing a new ADC platform based on the KIRAVIA Backbone as a linker, and Astellas will conduct non-clinical trials of development candidates. The collaboration will strengthen Astellas’ ability to utilize modalities and broaden Sony’s technological capabilities to develop anti-cancer drug therapy.
In conclusion, Sony and Astellas’ new collaborative research agreement signifies a promising development in the field of oncology. With the expected discovery of a novel ADC platform, patients around the world may look forward to a more effective and less intrusive treatment for cancer. The useful technology of KIRAVIA Backbone is expected to be an asset in further drug discovery.
– The focus Area Approach is the multidimensional approach established by Astellas for its research and development strategy.
– ADC is expected to selectively deliver anti-cancer drugs to target cells, reducing the side effects caused by drugs attacking normal cells.
– KIRAVIA Backbone is highly stable, increases the number of drugs to be added, and is water-soluble.
– Sony and Astellas have entered a collaborative research partnership aimed at developing a new Antibody-Drug Conjugate (ADC) platform that will improve the efficacy of treatment and reduce side effects in the oncology field.
– The use of Sony’s unique polymeric material, KIRAVIA Backbone, is key to this partnership as it improves therapeutic efficacy by achieving high Drug-to-Antibody Ratio (DAR) and increases capacity and solubility.
– The partnership will strengthen Astellas’ ability to utilize modalities, and Sony’s technological capabilities in the development of anti-cancer drug therapy.
In conclusion, Sony and Astellas’ new partnership is a promising development in the oncology field that could lead to more efficient and effective treatments for cancer patients globally.